W. R. Berkley (WRB) EPS Estimated At $0.76; Corvus Pharmaceuticals (CRVS) Sellers Decreased By 13.07% Their Shorts

January 18, 2018 - By Adrian Erickson

Corvus Pharmaceuticals Incorporated (NASDAQ:CRVS) had a decrease of 13.07% in short interest. CRVS’s SI was 1.03M shares in January as released by FINRA. Its down 13.07% from 1.19 million shares previously. With 114,100 avg volume, 9 days are for Corvus Pharmaceuticals Incorporated (NASDAQ:CRVS)’s short sellers to cover CRVS’s short positions. The SI to Corvus Pharmaceuticals Incorporated’s float is 12.13%. The stock increased 0.10% or $0.01 during the last trading session, reaching $9.99. About 27,754 shares traded. Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) has declined 11.61% since January 18, 2017 and is downtrending. It has underperformed by 28.31% the S&P500.

Analysts expect W. R. Berkley Corporation (NYSE:WRB) to report $0.76 EPS on January, 30.They anticipate $0.06 EPS change or 7.32% from last quarter’s $0.82 EPS. WRB’s profit would be $92.56 million giving it 23.06 P/E if the $0.76 EPS is correct. After having $0.36 EPS previously, W. R. Berkley Corporation’s analysts see 111.11% EPS growth. The stock increased 0.99% or $0.69 during the last trading session, reaching $70.11. About 293,907 shares traded. W. R. Berkley Corporation (NYSE:WRB) has risen 22.62% since January 18, 2017 and is uptrending. It has outperformed by 5.92% the S&P500.

W. R. Berkley Corporation, an insurance holding company, operates as commercial lines writer in the United States and internationally. The company has market cap of $8.54 billion. It operates through two divisions, Insurance and Reinsurance. It has a 16.58 P/E ratio. The Insurance segment underwrites insurance business, including premises operations, commercial automobile, property, products liability, and professional liability lines.

Among 10 analysts covering W.R. Berkley (NYSE:WRB), 1 have Buy rating, 1 Sell and 8 Hold. Therefore 10% are positive. W.R. Berkley had 21 analyst reports since July 28, 2015 according to SRatingsIntel. The rating was maintained by RBC Capital Markets on Monday, October 2 with “Hold”. The firm has “Sell” rating given on Wednesday, October 25 by UBS. The rating was upgraded by Morgan Stanley on Thursday, January 21 to “Equal-Weight”. Macquarie Research upgraded the stock to “Outperform” rating in Tuesday, January 17 report. Bank of America maintained W. R. Berkley Corporation (NYSE:WRB) rating on Wednesday, October 25. Bank of America has “Neutral” rating and $74 target. The firm has “Neutral” rating given on Tuesday, October 13 by Compass Point. Deutsche Bank maintained W. R. Berkley Corporation (NYSE:WRB) on Wednesday, October 25 with “Hold” rating. The company was maintained on Wednesday, February 3 by RBC Capital Markets. The stock has “Hold” rating by Keefe Bruyette & Woods on Friday, September 1. Keefe Bruyette & Woods maintained W. R. Berkley Corporation (NYSE:WRB) rating on Thursday, December 21. Keefe Bruyette & Woods has “Hold” rating and $72.0 target.

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of novel immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. The company has market cap of $210.20 million. The Company’s lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint. It currently has negative earnings. The firm is also developing an anti-CD73 monoclonal antibody that inhibits the production of adenosine; an antagonist of the adenosine A2B receptor; and small molecule covalent inhibitors of interleukin-2 inducible kinase.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:

Recent Posts